ABBV logo

ABBV
Abbvie Inc

32,556
Mkt Cap
$373.77B
Volume
6.34M
52W High
$244.81
52W Low
$176.57
PE Ratio
101.62
ABBV Fundamentals
Price
$206.60
Prev Close
$211.32
Open
$211.00
50D MA
$214.54
Beta
0.36
Avg. Volume
6.84M
EPS (Annual)
$2.36
P/B
-111.69
Rev/Employee
$1.07M
$468,276.79
Loading...
Loading...
Poll

Earnings Recap

• Reported GAAP EPS of $0.39 down -45.83% YoY • Reported revenue of $15B up 12.43% YoY • AbbVie is raising its adjusted diluted EPS guidance for the full year 2026 from $13.96 - $14.16 to $14.08 - $14.28, including an unfavorable $0.41 per share impact from IPR&D.

Bullish

AbbVie saw strong growth in immunology and neuroscience portfolios, advanced its pipeline with new drug approvals and positive clinical trial results, and invested in new manufacturing and R&D infrastructure.

Bearish

AbbVie experienced significant revenue declines in Humira and Imbruvica, faced an unfavorable $0.41 per share impact from IPR&D expense, and received a Complete Response Letter from the FDA for trenibotulinumtoxinE.

Latest ABBV News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.